Molecular Profile Detail

Profile Name CTNNB1 S45F
Gene Variant Detail

CTNNB1 S45F (gain of function)

Relevant Treatment Approaches CTNNB1 Inhibitor PDPK1 Inhibitor Tankyrase Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable CTNNB1 Inhibitor RX-5902 Phase I Actionable In a Phase I trial, RX-5902 treatment resulted in stable disease in 43% (15/35) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 258P; NCT02003092). detail...
Unknown unknown pancreatic adenocarcinoma not applicable CTNNB1 Inhibitor Gemcitabine + Pri-724 Phase Ib/II Actionable In a Phase Ib trial, the combination of PRI-724 and Gemzar (gemcitabine) demonstrated safety and preliminary efficacy in patients with advanced pancreatic adenocarcinoma, resulted in stable disease in 40% (8/20) of the patients, with a median progression-free survival of 2 months, and a median decline of serum S100P level by 49.95% (Journal of Clinical Oncology 34, no. 15_suppl; NCT01764477). detail... detail...
Unknown unknown Advanced Solid Tumor not applicable CTNNB1 Inhibitor Pri-724 Phase I Actionable In a Phase I trial, Pri-724 displayed safety and preliminary efficacy in patients with a variety of advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 2501)). detail...
Unknown unknown gastrointestinal stromal tumor not applicable CTNNB1 Inhibitor PKF118-310 Preclinical - Cell line xenograft Actionable In a preclinical study, PKF118-310 decreased viability of gastrointestinal stromal tumor (GIST) cell lines in culture, and reduced tumor growth in xenograft models (PMID: 28611108). 28611108
Unknown unknown hepatocellular carcinoma not applicable CTNNB1 Inhibitor FH535 Preclinical Actionable In a preclinical study, FH535 demonstrated efficacy by inhibiting proliferation of liver cancer stem cells and hepatocellular carcinoma cells in culture (PMID: 24940873). 24940873
Unknown unknown liver cancer not applicable CTNNB1 Inhibitor FH535 Preclinical Actionable In a preclinical study, FH535 demonstrated efficacy by inhibiting proliferation of liver cancer stem cells and hepatocellular carcinoma cells in culture (PMID: 24940873). 24940873
Unknown unknown colon cancer not applicable CTNNB1 Inhibitor LF3 Preclinical - Cell line xenograft Actionable In a preclinical study, LF3 decreased expression of Wnt target genes and reduced tumor growth in colon cancer cell line xenograft models derived from cells with high levels of Wnt signaling (PMID: 26645562). 26645562
Unknown unknown multiple myeloma not applicable CTNNB1 Inhibitor BC2059 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with BC2059 decreased proliferation and induced apoptosis of several human multiple myeloma cell lines and primary multiple myeloma cells with activated canonical Wnt signaling in culture, and delayed tumor growth in a multiple myeloma cell line xenograft model (PMID: 28500235). 28500235
Unknown unknown multiple myeloma not applicable CTNNB1 Inhibitor BC2059 + Bortezomib Preclinical - Patient cell culture Actionable In a preclinical study, the combination of BC2059 and Velcade (bortezomib) worked additively or synergistically in several human multiple myeloma cell lines and primary multiple myeloma cells with activated canonical Wnt signaling in culture (PMID: 28500235). 28500235
Unknown unknown breast cancer not applicable CTNNB1 Inhibitor CWP232228 Preclinical - Cell line xenograft Actionable In a preclinical study, CWP232228 inhibited Wnt pathway signaling, inhibited growth of breast cancer stem cells, and reduced tumor growth in breast cancer xenograft models (PMID: 25660951). 25660951
Unknown unknown Advanced Solid Tumor not applicable PDPK1 Inhibitor OSU03012 Phase I Actionable In a Phase I trial, OSU03012 (AR-12) treatment demonstrated safety and resulted in stable disease in 6% (2/30) of patients with advanced solid tumors, however, a new formulation was recommended due to limited absorption of the drug (J Clin Oncol 31, 2013 (suppl; abstr 2608)). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable PDPK1 Inhibitor SNS-510 Preclinical - Cell culture Actionable In a preclinical study, treatment with SNS-510 decreased PDPK1 pathway signaling and proliferation of a diffuse large B-cell lymphoma cell line in culture (Mol Cancer Ther, Dec 1 2015 (14) (12 Supplement 2) C198). detail...
Unknown unknown multiple myeloma not applicable PDPK1 Inhibitor SNS-510 Preclinical - Cell culture Actionable In a preclinical study, treatment with SNS-510 decreased PDPK1 pathway signaling and proliferation of multiple myeloma cell lines in culture (Mol Cancer Ther, Dec 1 2015 (14) (12 Supplement 2) C198). detail...
Unknown unknown acute myeloid leukemia not applicable PDPK1 Inhibitor SNS-510 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with SNS-510 decreased PDPK1 pathway signaling and reduced proliferation of acute myeloid leukemia (AML) cell lines in culture, and inhibited tumor growth in an AML cell line xenograft model (Mol Cancer Ther, Dec 1 2015 (14) (12 Supplement 2) C198). detail...
Unknown unknown acute myeloid leukemia not applicable PDPK1 Inhibitor SNS-229 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with SNS-229 resulted in decreased PDPK1 pathway signaling and tumor growth inhibition in an acute myeloid leukemia cell line xenograft model (Mol Cancer Ther, Dec 1 2015 (14) (12 Supplement 2) C198). detail...
Unknown unknown gastrointestinal stromal tumor not applicable Tankyrase Inhibitor G007-LK Preclinical Actionable In a preclinical study, G007-LK demonstrated anti-tumor activity in a mouse model of gastrointestinal stromal tumor expressing Kit V558del (corresponding to human V559del) (PMID: 28611108). 28611108
Unknown unknown breast cancer not applicable Tankyrase Inhibitor Carboplatin + E7449 Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of E7449 and Paraplatin (carboplatin) synergized to inhibit tumor growth in a human breast cancer cell line xenograft model (PMID: 26513298). 26513298
Unknown unknown melanoma not applicable Tankyrase Inhibitor E7449 + Temozolomide Preclinical Actionable In a preclinical study, the combination of E7449 and Temodar (temozolomide) inhibited tumor growth in mouse melanoma models, with increased efficacy compared to either agent alone (PMID: 26513298). 26513298
Clinical Trial Phase Therapies Title Recruitment Status